

### **REMARKS**

Claims 1-32 constitute the pending claims in the present application. Claims 33-49 were cancelled in the Preliminary Amendment of October 10, 2003. As requested by the Examiner, Applicants have amended claims 5 and 6 to provide a reference to the appropriate sequence identifiers. Applicants' amendments are made solely for clarity and do not alter the scope of claims 5 and 6.

Applicants add new claim 50. Claim 50 incorporates all of the limitations of claims 1, 18, and 30. Claim 50 is fully supported by the specification, and no new matter has been entered.

In the Restriction Requirement mailed August 1, 2006, claims 1-32 were classified as the invention of Group I. However, the Restriction Requirement did require Applicants to make certain species elections. Specifically, Applicants must elect, for search purposes only, a species of linker moiety (species election A) and a species of binding domain (species election B). Applicants elect with traverse the following species for search purposes only: a peptidyl linker (election A – species of linker moiety, see for example claim 18) and a therapeutic agent (election B – species of binding domain, see for example claims 30 and 31).

Applicants elect the foregoing species with traverse because claims 1-32 are directed to overlapping subject matter. Although searches of the various species cited by the Examiner may not be identical, such searches are sufficiently co-extensive so as not to constitute an undue burden. Accordingly, Applicants respectfully request withdrawal of the required species election.

Applicants note that claims 1 and 2 are generic to all of the elected species. Applicants note that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species.


Furthermore, claims 1-13, 18-20, and 24-31 read on elected species A and claims 1-28 and 30-32 read on elected species B. Claims 1-13, 18-20, 24-28, 30, and 31 read on both of the elected species. Additionally, Applicants note that new claim 50 reads on both elected species.

**CONCLUSION**

Claims 1-32 constitute the pending claims in the present application. Applicants elect with traverse the following species for search purposes only: a peptidyl linker and a therapeutic agent. If any clarification of the above response would facilitate prosecution of this application, Applicants respectfully request that the Examiner contact the undersigned at 617-951-7000. Should an extension of time be required, Applicants hereby petition for same and request that the extension fee and any other fee required for timely consideration of this submission be charged to **Deposit Account No. 18-1945, under Order No. CIBT-P02-130.**

Date: December 19, 2006

Respectfully Submitted,



---

Melissa S. Rones  
Reg. No. 54,408  
Ropes & Gray LLP  
One International Place  
Boston, MA 02110  
Phone: 617-951-7000  
Fax: 617-951-7050